U.S. markets closed
  • S&P Futures

    4,360.50
    +11.50 (+0.26%)
     
  • Dow Futures

    34,241.00
    +56.00 (+0.16%)
     
  • Nasdaq Futures

    14,219.75
    +79.00 (+0.56%)
     
  • Russell 2000 Futures

    2,001.00
    -0.30 (-0.01%)
     
  • Crude Oil

    85.23
    -0.37 (-0.43%)
     
  • Gold

    1,846.90
    -5.60 (-0.30%)
     
  • Silver

    23.76
    -0.13 (-0.55%)
     
  • EUR/USD

    1.1308
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.7830
    +0.0480 (+2.77%)
     
  • Vix

    31.16
    +1.26 (+4.21%)
     
  • GBP/USD

    1.3512
    +0.0006 (+0.05%)
     
  • USD/JPY

    113.8850
    +0.0190 (+0.02%)
     
  • BTC-USD

    37,316.12
    +944.23 (+2.60%)
     
  • CMC Crypto 200

    848.80
    +28.21 (+3.44%)
     
  • FTSE 100

    7,371.46
    +74.31 (+1.02%)
     
  • Nikkei 225

    27,124.30
    -7.04 (-0.03%)
     

How Many Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Do Institutions Own?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • RLAY

If you want to know who really controls Relay Therapeutics, Inc. (NASDAQ:RLAY), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Companies that used to be publicly owned tend to have lower insider ownership.

With a market capitalization of US$3.8b, Relay Therapeutics is rather large. We'd expect to see institutional investors on the register. Companies of this size are usually well known to retail investors, too. Our analysis of the ownership of the company, below, shows that institutions own shares in the company. Let's delve deeper into each type of owner, to discover more about Relay Therapeutics.

See our latest analysis for Relay Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Relay Therapeutics?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that Relay Therapeutics does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Relay Therapeutics' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Hedge funds don't have many shares in Relay Therapeutics. SoftBank Investment Advisers (UK) Limited is currently the company's largest shareholder with 26% of shares outstanding. With 9.6% and 5.0% of the shares outstanding respectively, FMR LLC and BlackRock, Inc. are the second and third largest shareholders. In addition, we found that Sanjiv Patel, the CEO has 0.9% of the shares allocated to their name.

On further inspection, we found that more than half the company's shares are owned by the top 6 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Relay Therapeutics

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

Our most recent data indicates that insiders own some shares in Relay Therapeutics, Inc.. This is a big company, so it is good to see this level of alignment. Insiders own US$95m worth of shares (at current prices). If you would like to explore the question of insider alignment, you can click here to see if insiders have been buying or selling.

General Public Ownership

The general public-- including retail investors -- own 10% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Equity Ownership

With an ownership of 26%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 3 warning signs for Relay Therapeutics you should be aware of.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.